Stockholm, August 21, 2024 – Purpose Pharma International AB is pleased to announce that Eir Ventures has invested in an extension of the Series A financing completed in 2023.

Purpose Pharma is a patient-centric European based pharmaceutical company focusing on the development and commercialization of novel rare disease and specialty care products in areas of high unmet medical need. The company is founded and led by an experienced team, including Jonas Hansson, former CEO of Wilson Therapeutics and venture partner at HealthCap, Jacob Gunterberg, previously partner at HealthCap and Lars Olsson, a seasoned pharmaceutical developer.

Eir Ventures now joins Industrifonden in an extension of the Series A financing completed in 2023 and Tobias Horneman-Thielcke has been elected board member representing Eir Ventures.

“We are very excited about joining Purpose Pharma and being part of this journey,” says Tobias Horneman-Thielcke with Eir Ventures.

Purpose Pharma is organized in two business areas: Specialty/Proprietary Products and Unlicensed Medicines. In the Specialty/Proprietary Products business area, it is the company’s mission to identify and develop niche products for commercialization, initially focusing on the Nordics and over time expanding into other European markets. The company has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for its first product, diflunisal, for the treatment of transthyretin amyloid polyneuropathy (ATTR-PN), a rare and debilitating disease and for which orphan drug designation has been granted. The Unlicensed Medicines business area focuses on the Swedish market and has the objective to provide drugs which are currently not registered in Sweden and to address drug shortages.

“We are happy to welcome Eir Ventures to Purpose Pharma and look forward to expanding the business by addressing patient and market needs,” says Jonas Hansson, CEO of Purpose Pharma.

For more information about Purpose Pharma and its mission, visit purposepharma.com.

About Eir Ventures

Eir Ventures I AB is a Nordic life science venture capital fund that invests in private companies with outstanding entrepreneurs developing transformative therapeutic approaches. The fund commenced its investment activities in 2020 and invests in opportunities addressing significant unmet medical needs for new therapies, medical technology, and digital health. Eir Ventures AB is led by a team of experienced life science investors and is supported by a strong investor syndicate consisting of leading local and international institutional investors and, uniquely, leading Nordic universities. www.eirventures.eu